Status:
UNKNOWN
Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborating Sponsors:
Ruijin Hospital
Fudan University
Conditions:
Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST
Eligibility:
All Genders
14-80 years
Brief Summary
Evaluate the reliability of morphology standards for GIST pathologic type, staging and grading by retrospective analyzing clinical data; on this basis, establish a GIST standardized and individualized...
Detailed Description
1. Retrospective analysis of GIST cases in the recent five years: the GIST clinical data of Fudan University Zhongshan Hospital from 2007 January to 2012 December were collected. By reviewing the HE s...
Eligibility Criteria
Inclusion
- All patients pathologically diagnosed with GIST during the period from 2017 to 2020
Exclusion
- Only have Biopsy diagnosis
- Only have Liver metastasis or peritoneal dissemination
- Received imatinib treatment before surgery
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT03381053
Start Date
July 1 2017
End Date
January 1 2022
Last Update
December 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, Shanghai Municipality, China, 200032